Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis
Waxman AJ, Clasen S, Hwang WT et al.
Allergy and Clinical Immunology; Cardiology; Heart Failure; Hematology; Hypertension; Myeloma; Oncology; Toxicology; Hematologic Cancer
IMPORTANCE - Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized. We performed the first systematic review and meta-analysis of carfilzomib-associated CVAE.
http://www.cbsmd.cn Contact us by email@example.com
Copyright ⓒ CBSMD Nanjing China. All rights reserved.